Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study

Published:2010-05-19 Issue:6 Volume:16 Page:910-918
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

SPIRA J.,PLYUSHCH O.,ZOZULYA N.,YATUV R.,DAYAN I.,BLEICHER A.,ROBINSON M.,BARU M.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02273.x/fullpdf

Reference36 articles.

1. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy;Hedner;Lancet,1988

2. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group;Lusher;Haemophilia,1998

3. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects;Fridberg;Blood Coagul Fibrinolysis,2005

4. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa;Lindley;Clin Pharmacol Ther,1994

5. Home treatment with recombinant activated factor VII: results from one centre;Ingerslev;Blood Coagul Fibrinolysis,1998

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review;Journal of Thrombosis and Haemostasis;2022-04

2. An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review;Nanoscale Advances;2021

3. Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free anticoagulant activity;Nanomedicine;2020-06

4. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations;Research and Practice in Thrombosis and Haemostasis;2018-05-20

5. Understanding Nanoparticle Immunotoxicity to Develop Safe Medical Devices;The Immune Response to Implanted Materials and Devices;2016-12-01